王添

[關(guān)鍵詞] 哮喘;長(zhǎng)期控制不佳;糖皮質(zhì)激素;支氣管擴(kuò)張劑;臨床作用

[中圖分類(lèi)號(hào)] R562? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] B? ? ? ? ? [文章編號(hào)] 1673-9701（2021）21-0090-03

Analysis on the clinical efficacy of glucocorticoid combined with bronchodilator in the treatment of asthma patients with long term poor control

WANG Tian

Department of Infectious Disease，the Second Affiliated Hospital of Shenyang Medical College， Shenyang 110002， China

[Abstract] Objective To explore the clinical efficacy of glucocorticoid combined with bronchodilator in the treatment of asthma patients with long term poor control. Methods A total of 100 asthma patients with long term poor control admitted to and treated in our hospital from January 2018 to June 2020 were selected for research， and they were divided into the control group （n=50） and the observation group （n=50） according to the random number table method. The control group was treated with bronchodilator， while the observation group was treated with glucocorticoid on the basis of the control group. The clinical efficacies of the two groups were appraised， the asthma control test （ACT） scores before and after treatment were evaluated， the levels of serum interleukin-4（IL-4） and interleukin-8 （IL-8） before and after treatment were detected，and the results between the two groups were compared and analyzed. Results The total effective rate of the observation group was 98.00%，which was higher than 80.00% of the control group（P<0.05）. Before treatment，there was no statistically significant differences in ACT scores， levels of serum IL-4 and IL-8 between the two groups （P>0.05）. After treatment， the ACT scores， levels of serum IL-4 and IL-8 of the observation group were （4.32±0.42） points， （12.10±3.42） ng/L，（70.69±5.94）ng/L， while those of the control group were （3.41±0.55）points， （18.75±5.43）ng/L， （90.04±6.85） ng/L， respectively，with statistically significant differences between the two groups（P<0.05）. Conclusion Long term poorly controlled asthma can be treated with glucocorticoid combined with bronchodilator， which can improve the therapeutic efficacy， ACT score and serum inflammatory index， and is worthy of application.

[Key words] Asthma; Long term poor control; Glucocorticoid; Bronchodilator; Clinical efficacy

哮喘也稱(chēng)支氣管哮喘，是臨床常見(jiàn)呼吸科疾病，是多種細(xì)胞或細(xì)胞組分導(dǎo)致的慢性氣道炎癥病變，可進(jìn)而誘發(fā)氣道反應(yīng)性增高。哮喘患者多有氣促、咳嗽、喘息等癥狀，且癥狀好發(fā)于夜間、凌晨，對(duì)患者的睡眠質(zhì)量造成嚴(yán)重影響，進(jìn)而影響他們正常的學(xué)習(xí)、工作和生活，導(dǎo)致生活質(zhì)量降低[1]。李倩倩等[2]研究發(fā)現(xiàn)哮喘還受遺傳因素、環(huán)境因素、病毒感染、精神因素等的影響，因此在臨床生活中應(yīng)做好防控，盡量減少哮喘發(fā)生，一旦罹患此病，藥物治療是首選療法，但不同的藥物治療效果不一，且單用藥物方案治療控制效果不佳，尤其是老年患者合并基礎(chǔ)疾病較多，病情較重，治療難度大，復(fù)發(fā)率高[3]。目前從臨床治療來(lái)看，哮喘長(zhǎng)期控制不佳患者是治療的重難點(diǎn)，隨著近幾年聯(lián)合用藥方案的指征擴(kuò)大，在一些報(bào)道中發(fā)現(xiàn)聯(lián)合用藥可提高預(yù)后，成為研究熱點(diǎn)。為進(jìn)一步探究哮喘長(zhǎng)期控制不佳患者應(yīng)用糖皮質(zhì)激素聯(lián)合支氣管擴(kuò)張劑治療的臨床作用，我院對(duì)2018年1月至2020年6月收治的100例患者進(jìn)行分組研究，現(xiàn)報(bào)道如下。